Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RELV
2676
DELISTED
Reliv International Inc
RELV
| $707K | ﹤0.01% |
80,580
+9,600
| +14% | +$68.4K |
|
|
SCTL
2677
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $706K | ﹤0.01% |
111,946
+41,143
| +58% | +$282K |
|
|
CWAY
2678
DELISTED
Coastway Bancorp, Inc.
CWAY
| $704K | ﹤0.01% |
34,351
-2,049
| -6% | -$40.4K |
|
|
LUNA
2679
DELISTED
Luna Innovations Incorporated
LUNA
| $704K | ﹤0.01% |
465,905
+29,200
| +7% | +$44.9K |
|
|
TIS
2680
DELISTED
Orchids Paper Products, Inc.
TIS
| $693K | ﹤0.01% |
53,500
-8,500
| -14% | -$145K |
|
|
ENFY
2681
DELISTED
Enlightify Inc
ENFY
| $692K | ﹤0.01% |
45,067
+3,029
| +7% | +$46.1K |
|
|
BKEP
2682
DELISTED
Blueknight Energy Partners L.P.
BKEP
| $689K | ﹤0.01% |
110,244
-21,850
| -17% | -$148K |
|
2683
ReposiTrak
TRAK
$152M
| $683K | ﹤0.01% |
56,227
-31,373
| -36% | -$386K |
|
2684
ImmunityBio
IBRX
$8.11B
| $679K | ﹤0.01% |
89,400
-396,700
| -82% | -$1.71M |
|
2685
Galicia Financial Group
GGAL
$7.1B
| $678K | ﹤0.01% |
+15,900
| New | +$663K |
|
|
FWDI
2686
Forward Industries Inc
FWDI
$305M
| $668K | ﹤0.01% |
63,570
+750
| +1% | +$8.35K |
|
2687
Coffee Holding Co
JVA
$20.2M
| $660K | ﹤0.01% |
148,300
+8,200
| +6% | +$38.3K |
|
|
SCU
2688
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
| $660K | ﹤0.01% |
25,790
+9,660
| +60% | +$229K |
|
|
BPMC
2689
DELISTED
Blueprint Medicines
BPMC
| $659K | ﹤0.01% |
13,000
-24,400
| -65% | -$1.04M |
|
|
NADL
2690
DELISTED
North Atlantic Drilling Ltd
NADL
| $655K | ﹤0.01% |
492,640
+65,800
| +15% | +$138K |
|
2691
Mitek Systems
MITK
$838M
| $651K | ﹤0.01% |
+77,476
| New | +$632K |
|
|
NEWS
2692
DELISTED
NewStar Financial, Inc.
NEWS
| $651K | ﹤0.01% |
62,000
-58,400
| -49% | -$592K |
|
2693
Willamette Valley Vineyards
WVVI
$12M
| $650K | ﹤0.01% |
80,400
+17,800
| +28% | +$142K |
|
|
SGY
2694
DELISTED
Stone Energy
SGY
| $649K | ﹤0.01% |
+35,300
| New | +$754K |
|
2695
Security National Financial
SNFCA
$242M
| $644K | ﹤0.01% |
160,670
-318
| -0.2% | -$1.31K |
|
2696
Inseego
INSG
$82.6M
| $642K | ﹤0.01% |
51,380
-16,060
| -24% | -$248K |
|
2697
TD Synnex
SNX
$20.4B
| $636K | ﹤0.01% |
10,602
-176,598
| -94% | -$9.88M |
|
|
ENG
2698
DELISTED
ENGlobal Corp
ENG
| $636K | ﹤0.01% |
61,596
-2,069
| -3% | -$23.3K |
|
|
HTM
2699
DELISTED
U.S. Geothermal Inc.
HTM
| $636K | ﹤0.01% |
138,649
-26,400
| -16% | -$108K |
|
|
GPX
2700
DELISTED
GP Strategies Corp.
GPX
| $634K | ﹤0.01% |
23,999
-22,660
| -49% | -$577K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.